High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort
Authors:
- 12 September 2014
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 30 (3) , 515-521
Abstract
Background Exposure to gadolinium-based contrast agents (GBCA) in patients with chronic kidney disease (CKD) has been associated with the development of a potentially fatal disorder, nephrogenic systemic fibrosis (NSF). Although contrast-enhanced computed tomography (CT) is an alternative to magnetic resonance imaging (MRI), it carries the risk of radiation exposure and further reduction of residual renal function. Therefore we sought to assess the feasibility of ferumoxytol as an alternative to GBCA for contrast-enhanced MR angiography (MRA) in a pediatric cohort with CKD. Ferumoxytol is a parenteral iron supplement that contains ultrasmall superparamagnetic iron oxide (USPIO) and is a potent relaxivity agent for MRI. Methods We describe the MRI findings in ten pediatric patients who needed detailed vascular mapping. Ferumoxytol (4 mg/kg) was administered intravenously for contrast-enhanced MRA. The patients tolerated the procedure without complications. Results Resulting studies were highly diagnostic and were pivotal in guiding patient management. The images were notable for clear delineation of multiple vascular occlusions. Conclusions Given the concerns associated with the use of GBCAs in renal failure, ferumoxytol is an excellent alternative contrast agent in pediatric end stage renal disease (ESRD) patients. Future studies are needed in order to further evaluate safety and efficacy of ferumoxytol in this patient population.Keywords
This publication has 28 references indexed in Scilit:
- Abdominopelvic and Lower Extremity Deep Venous Thrombosis: Evaluation With Contrast-Enhanced MR Venography With a Blood-Pool AgentAmerican Journal of Roentgenology, 2013
- Ferumoxytol Use as an Intravenous Contrast Agent for Magnetic Resonance AngiographyAnnals of Pharmacotherapy, 2011
- Incidence of Immediate Gadolinium Contrast Media ReactionsAmerican Journal of Roentgenology, 2011
- Potential for Differentiation of Pseudoprogression From True Tumor Progression With Dynamic Susceptibility-Weighted Contrast-Enhanced Magnetic Resonance Imaging Using Ferumoxytol vs. Gadoteridol: A Pilot StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Superparamagnetic Iron Oxide Nanoparticles: Diagnostic Magnetic Resonance Imaging and Potential Therapeutic Applications in Neurooncology and Central Nervous System Inflammatory Pathologies, a ReviewJournal of Cerebral Blood Flow & Metabolism, 2009
- Ferumoxytol for Treating Iron Deficiency Anemia in CKDJournal of the American Society of Nephrology, 2008
- High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast AgentInvestigative Radiology, 2008
- New Insights into Nephrogenic Systemic FibrosisJournal of the American Society of Nephrology, 2007
- Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrology Dialysis Transplantation, 2006
- A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRIJournal of X-Ray Science and Technology, 2003